Pulmonx Q1 2024 GAAP EPS $(0.36) Beats $(0.46) Estimate, Sales $18.854M Beat $17.893M Estimate
Pulmonx Q1 2024 GAAP EPS $(0.36) Beats $(0.46) Estimate, Sales $18.854M Beat $17.893M Estimate
Pulmonx 2024年第一季度GAAP每股收益美元（0.36）超過預期（0.46），銷售額爲1885.4萬美元，超過預期的1789.3萬美元
Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.46) by 21.74 percent. This is a 14.29 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $18.854 million which beat the analyst consensus estimate of $17.893 million by 5.37 percent. This is a 29.71 percent increase over sales of $14.535 million the same period last year.
Pulmonx（納斯達克股票代碼：LUNG）公佈的季度虧損爲每股0.36美元，比分析師普遍預期的0.46美元（0.46美元）高出21.74％。與去年同期每股虧損0.42美元（0.42）相比，增長了14.29％。該公司公佈的季度銷售額爲188.54萬美元，比分析師共識估計的1789.3萬美元高出5.37％。這比去年同期的1453.5萬美元的銷售額增長了29.71％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。